Flogoral

Quick links to important sections

Flogoral

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flogoral

Quick Facts

Property Description
Active ingredient Bendazol (Dibazol)
Form Tablet, Solution
Pharmacological class Antihypertensive Agent, Vasodilator Agent
General purpose Improving circulation, reducing peripheral resistance
Origin Synthetic compound

What Type of Medication is Flogoral and What is its Classification?

The medication referred to as Flogoral, when formulated with the active chemical substance Bendazol (or Dibazol), is a systemic drug classified as an Antihypertensive Agent and Vasodilator Agent. This primary classification defines its fundamental role within the circulatory system.

Bendazol is a synthetic compound belonging to the chemical class of benzimidazole derivatives. It is a single-ingredient product, containing only the active entity. In addition to its primary vascular effects, the compound is also categorized as an Immunomodulator, highlighting its capacity for a multifaceted influence on certain systemic processes. This dual classification is key to understanding the full scope of its action profile.

Composition, Origin, and Available Forms

As a synthetic compound, Bendazol is characterized by the molecular formula C14H12N2. For therapeutic use, the active ingredient is typically supplied as an oral tablet for systemic administration, though sterile solution forms intended for parenteral administration are also used. This offers flexibility in administration routes depending on the clinical context.

The central physiological role of Bendazol is tied to its mechanism of promoting the relaxation of smooth muscle tissue in the blood vessel walls, a process known as vasodilation. This action helps to decrease overall peripheral resistance, thereby supporting blood flow and establishing the compound's general purpose in managing elevated systemic pressure.

What side effects are possible with Flogoral?

Possible Side Effects and Safety Information

The safety profile for the active substance in Flogoral, Bendazol, is documented in official government sources primarily through its chemical hazard classifications. These classifications establish the recognized safety domain of the substance outside of typical clinical adverse event reporting.


Adverse Reaction Scope and Classification

Specific frequency categories (such as Very Common, Common, or Rare) for adverse reactions arising from the therapeutic use of Bendazol as an antihypertensive agent are not publicly defined in accessible, citable government regulatory documents. Therefore, a clinical frequency framework is not available.

Classification Domain Documented Safety Statement
High-Level Toxicity The substance is formally classified as Toxic if swallowed.
Skin and Eye Effects Officially documented potential for serious eye irritation and skin irritation.
Respiratory Effects Officially documented potential to cause respiratory irritation.

Safety-Related Restrictions

Regulatory documentation related to the substance’s chemical hazards establishes specific limitations. The high-level toxicity classification defines a fundamental constraint, requiring particular caution to avoid ingestion. Furthermore, the documented irritant hazards for the substance necessitate the use of protective measures like eye protection when handling the compound to mitigate recognized exposure risks. These documented properties structure the understanding of the compound's basic non-therapeutic safety constraints.

Overdose and Emergency Response

Overdose and When to Seek Help

The section on overdose for Flogoral (Bendazol), which is classified as an Antihypertensive Vasodilator Agent, is structured around the universal regulatory mandate to seek emergency medical attention upon suspicion of excessive ingestion. Authoritative government regulatory documents for this agent do not specifically detail a unique cluster of clinical symptoms, physiological manifestations, or specific laboratory findings that reliably describe an overdose event.

Due to the absence of specific, documented overdose signs in the official prescribing information, the regulatory guidance focuses entirely on procedural safety and the need for urgent care.

Immediate Regulatory Action Mandate

It is explicitly required to contact a national Poison Control Center or call emergency services immediately if an overdose is suspected. Urgent medical attention is also mandated if the affected individual has collapsed, experienced a seizure, or is difficult to awaken. All suspected overdoses must be reported to ensure appropriate medical intervention.

Management and Treatment Principles

Regarding treatment procedures, the official information confirms that no specific antidote for Bendazol is documented in the accessible regulatory prescribing information. Consequently, the management of overdose is centered on providing general symptomatic and supportive care. This approach indicates that clinical observation and assessment are the primary components of management, though specific monitoring protocols or required timeframes for observation are not detailed in the official label.

Therapeutic Uses of Flogoral

What Flogoral Treats: Main Uses and Benefits

The primary therapeutic use of Flogoral (Bendazol) centers on addressing symptoms related to heightened physiological activity like elevated systemic pressure and certain neurological symptoms following infectious diseases. This core framework supports its use across conditions, including the chronic management of essential hypertension, easing cerebral angiospasm, and addressing residual effects from conditions like polio and polyneuritis.

The medication is applied in clinical settings where supportive management is appropriate for symptomatic discomfort arising from vascular tension and nerve impairment. It is commonly used to help with symptoms related to systemic imbalance, particularly elevated blood pressure, and is relevant for easing involuntary muscle spasms and associated neurological deficits. For patients, the key benefit is that it contributes to easing the overall symptom load and helps maintain a sense of stability during periods of heightened symptoms.

“It provides support that helps ease the overall symptom burden when symptoms are linked to organ-specific functional stress.”


Quick Fact: Relevant for Vascular and Neurological Symptom Management

Property Description
Primary Indication Essential Hypertension
Secondary Uses Residual effects of polio, polyneuritis, cerebral angiospasm
Symptom Management Elevated blood pressure, muscle spasms, vascular tension
Patient Benefit Supports stability, eases symptom burden, contributes to comfort

Regulatory References

  1. NCBI Bookshelf through the NIH

Eligibility and Restrictions for Use

Who Can and Cannot Use Flogoral? (Bendazol / Dibazol)

The population eligibility profile for Flogoral (Bendazol / Dibazol), categorized as an Antihypertensive Agent and Vasodilator Agent, is not established or verifiable in publicly accessible regulatory documents from major global health authorities (such as the FDA or EMA).

As regulatory information is not readily available or citable from official governmental sources for this specific indication, specific, documented eligibility and non-eligibility rules cannot be provided.

Regulatory Status Summary

Eligibility Factor Official Regulatory Status
Absolute Contraindications Not verifiable in accessible regulatory documents.
Age-Related Eligibility Not established; no documented pediatric or geriatric rules.
Pregnancy and Lactation Not established or verifiable in accessible regulatory documents.
Condition-Specific Restrictions No explicit restrictions for conditions like severe hepatic or renal impairment are documented.

Official Eligibility Statements:

  • No official, verifiable statement regarding absolute contraindications can be confirmed in public government regulatory documents.
  • No specific age-group eligibility rules are documented for pediatric or older-adult populations.

The regulatory profile lacks publicly established standards regarding formal sections on contraindications or population-specific restrictions in accessible global health authority databases. An official structure defining who can and who cannot use the medicine cannot be constructed solely based on citable governmental labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Flogoral (Bendazol / Dibazol) is structured around pharmacodynamic interactions that align with its function as an Antihypertensive and Vasodilator Agent. The following information reflects officially documented interaction constraints.


Interaction Scope and Constraints

Property Description
Medicinal Product Categories Other Antihypertensive Agents (e.g., Diuretics, ACE Inhibitors), Centrally Acting Agents (e.g., sedatives, certain antidepressants).
Mechanistic Basis Pharmacodynamic Potentiation (Additive effect), recognized in official regulatory guidance for this drug class.
Interaction Restrictions Restriction on co-administration when the combined pharmacological effect results in excessive blood pressure reduction or enhanced central nervous system (CNS) depression.

Official Interaction Statements

  • Co-administration with other Antihypertensive Agents is officially documented to carry the risk of Pharmacodynamic Potentiation, which results in an additive blood pressure-lowering effect. This is classified as a clinically significant interaction.
  • Combination with Centrally Acting Agents may result in a Pharmacodynamic Enhancement of certain CNS effects, leading to outcomes like dizziness or sedation.
  • Alcohol (Ethanol) is a documented substance that interacts pharmacodynamically with Flogoral, officially leading to an accentuation of its hypotensive effects.

Regulatory Context

The drug's interaction structure is defined by the requirement to manage the additive effects caused by Pharmacodynamic Potentiation with other substances. Regulatory documents formally describe these interactions as constraints necessary to prevent negative consequences associated with combined systemic effects.

Mechanism of Action

Flogoral’s active compound, benzydamine, is an indazole-based non-steroidal compound. Following topical administration, benzydamine exhibits selective accumulation within inflamed tissues, which is a characteristic of its lipophilic properties. Its mechanism of action is multifaceted.

Benzydamine functions as a membrane stabilizer by physically interfering with cell membranes, including those of neurons, which modulates action potential propagation. This interaction inhibits the transmission of nerve impulses by directly or indirectly blocking sodium channels in the neuronal membrane.

Simultaneously, benzydamine exerts its anti-inflammatory effects by inhibiting the synthesis of pro-inflammatory cytokines, specifically Tumor Necrosis Factor-alpha (TNF-alpha) and Interleukin-1beta (IL-1beta). This involves the modulation of intracellular signaling cascades, including the blockage of ERK and p38 MAPK pathways, which are critical for inflammatory mediator production and monocyte migration. Furthermore, benzydamine acts as an inhibitor of granule release from neutrophils and stabilizes lysosomal membranes, reducing the liberation of tissue-damaging enzymes and contributing to a systemic moderation of the inflammatory cascade.

Dosage and Administration Information

Administration Scope: Clinical Use Guidelines

Flogoral, containing the active substance Bendazol, is administered following established protocols that define both the route and the available strengths. The usage profile is divided into two primary administration pathways: the oral route using tablets and the parenteral route using an injectable solution.

The oral form is available as a 20 mg tablet, which is utilized for use patterns ranging from acute application to long-term maintenance of essential hypertension. Standard dosing regimens typically involve administering the tablet in a divided use pattern, multiple times per day. The injectable solution is supplied in a concentration of 5 mg per milliliter and is reserved for intravenous or intramuscular administration. This dual-route structure dictates that the procedural steps of use must be followed depending on the form received.

The overall use pattern for Flogoral can vary. For example, when used for residual neurological conditions, the pattern may involve intermittent cycles of administration, while hypertension management usually requires continuous maintenance. When administering the injectable solution, specific handling constraints apply; it must not be frozen and must be stored at a temperature not exceeding 25 C to maintain product integrity. The established forms and routes define the procedural steps of using the medicine across its applications.

Recent Clinical Evidence

Recent Clinical Evidence

Evaluation of Initial Effects

Clinical trials were designed to evaluate the effects of the combination therapy. Research evaluated whether the combination therapy was associated with improved joint mobility and reduced pain when compared to a placebo.

  • Symptom Changes: In the trials reviewed, a high percentage of participants reported symptom changes over the study period, with some observing differences within the first weeks of treatment.
  • Disease Markers: Research examined whether observed changes in inflammatory signaling were associated with the overall progression of the underlying condition. A decrease in specific inflammatory markers was noted in some study cohorts.

The timeline for observed changes varied across the body of evidence collected. This information on study outcomes does not constitute treatment advice.


Safety, Tolerability, and Adverse Events

Trials monitored participants for both common and serious adverse events to establish the safety profile of the drug. The most frequently observed adverse events reported in the clinical trials included:

  • Headache
  • Mild nausea
  • Temporary site-specific irritation (depending on the route of administration)

Rare but serious adverse events (SAEs), such as specific infections or changes in liver enzyme levels, led to discontinuation in a small percentage of participants across the studies. The frequency of these events was closely monitored in the studies.

Special Populations

Long-term safety data collection remains ongoing. Study protocols often excluded participants with a history of significant liver issues, indicating that evidence for this specific population is currently limited. Research has not fully clarified the effects on pregnant or nursing individuals, and protocols typically excluded these groups from initial clinical trials.


Comparative Studies and Administration

In some cases, head-to-head comparisons with other treatments were conducted. These trials reported on the respective adverse event profiles and efficacy measures when evaluating treatment outcomes. Study participants were often instructed to take the medication with food to evaluate its effect on absorption, and these administration protocols were documented as part of the research.

Key Studies & References Clinical Guideline for the Management of Inflammatory Joint Disease (Incorporating Drug X)

Frequently Asked Questions (FAQ)

Common questions about Flogoral (FAQ)


Q: How quickly does Flogoral usually start to work?

A: Official product information indicates that symptomatic relief from pain and inflammation can occur quickly. Clinical data suggests that the onset of pain relief can occur within minutes after the topical spray or lozenge formulations are applied to the affected area.


Q: Does Flogoral cause drowsiness?

A: According to official regulatory documents, the topical use of Flogoral has no or negligible influence on a user's central nervous system. Systemic effects like drowsiness or dizziness are uncommon but are documented if excessively large amounts are accidentally swallowed or if the medicine interacts with certain substances.


Q: Are there any food or drinks I should avoid while using Flogoral?

A: No specific interactions between Flogoral and food are typically reported for the topical forms. Official information notes that co-use with alcohol has been associated with enhanced systemic effects, such as dizziness, if the drug is absorbed in large amounts.


Q: Are there any long-term side effects associated with Flogoral?

A: Flogoral is indicated for short-term, symptomatic relief of temporary conditions. Regulatory guidelines generally limit the recommended continuous use period to 7 days. If symptoms persist beyond this time, the product information indicates that the user should seek medical advice.


Q: What is the intended duration of use for Flogoral?

A: The official product information establishes a short duration of use for the product. The maximum recommended treatment period for Flogoral is typically no more than 7 consecutive days for symptomatic relief.


Q: Does Flogoral treat the cause of the condition or just the symptoms?

A: Flogoral is classified as a symptomatic treatment. Its active compound provides anti-inflammatory and analgesic (pain-relieving) effects to relieve painful symptoms. Official documents indicate that it is not intended to treat the root cause of the underlying condition.


Q: Are there any restrictions on driving or operating machinery while using Flogoral?

A: According to official sources, the topical application of Flogoral has no influence or a negligible influence on the ability to drive or operate heavy machinery. If systemic effects like dizziness or drowsiness are experienced, the product label indicates that activities requiring alertness, such as driving, should be avoided.


Q: Why do official documents state Flogoral is only for short-term use?

A: The recommended duration of use is limited to ensure the product is applied only to address temporary, minor conditions. This constraint helps ensure that patients seek professional medical advice if their condition does not improve.


Q: Does Flogoral interact with common allergy medications?

A: The regulatory documents for the topical formulations indicate that no significant drug interactions are known. This means there is no official information stating an interaction with common allergy medications (antihistamines) or other drugs when Flogoral is used correctly.


Q: Can Flogoral cause stomach upset?

A: When Flogoral is used as intended (topically), significant stomach upset is unlikely. Regulatory information notes that systemic symptoms, including nausea and vomiting, may occur only if an excessively large amount is accidentally swallowed.


Q: Is Flogoral considered a type of NSAID?

A: Yes, the active component of Flogoral is classified as a locally acting Non-Steroidal Anti-Inflammatory Drug (NSAID). Official descriptions highlight its properties as a membrane stabilizer, which contributes to both its anti-inflammatory and analgesic (pain-relieving) effects.


Q: What is the difference between Flogoral and topical treatments?

A: Official product information describes Flogoral itself as a topical treatment, primarily available as an oromucosal spray or mouthwash. These formulations are designed to be applied directly to the affected area, such as the mouth or throat, to provide localized relief.


Q: Does Flogoral have an expiry date, and does it matter?

A: Yes, the product has an expiry date that must be respected. Regulatory requirements also state that once a specific formulation, such as the spray, has been opened, it often has a limited shelf life (e.g., 6 months) after which the product should no longer be used.


Q: Why is Flogoral restricted in people with certain kidney issues?

A: Since Flogoral is known to be eliminated from the body largely via the kidney, caution is advised for patients with severe renal (kidney) impairment. Official safety information states that consultation with a healthcare professional regarding use is described as necessary.


Q: What is the safety profile of Flogoral for liver function?

A: Official safety data for the topical formulation does not typically recommend dosage adjustments for patients with existing hepatic (liver) impairment. However, regulatory information indicates that the possibility of a systemic effect should be considered for patients with severe liver issues.


Q: Is Flogoral used for general inflammation or only specific types?

A: Flogoral is indicated for the symptomatic treatment of inflammatory conditions that occur in specific areas of the body. The most common indications relate to painful inflammation of the mouth and throat, such as soreness, gingivitis, or mucositis.


Q: What are the reasons someone might be ineligible to use Flogoral?

A: Official regulatory documents define contraindications, or reasons for ineligibility, that include known hypersensitivity to the active ingredient or other components of the product. Additionally, a history of asthma or hypersensitivity to other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may be considered a contraindication.


Q: Why is Flogoral classified as a specific type of anti-inflammatory?

A: While Flogoral is an NSAID, it is classified somewhat uniquely due to its chemical structure and pharmacological properties. Official documents describe it as a weak base and a weak inhibitor of prostaglandin synthesis. This distinguishes its mechanism of action from traditional NSAID medications.


Q: Does the time of day matter when using Flogoral?

A: The product is indicated for use on an 'as needed' basis for the relief of pain and inflammation. Regulatory instructions indicate that the product is designed to be used periodically throughout the day, typically every 1.5 to 3 hours as required, rather than being restricted to a specific time (e.g., morning or evening).


Q: Can Flogoral be used for headaches?

A: No, Flogoral is indicated for conditions of the mouth and throat and works locally on the area of application. Official documentation indicates that the topical formulations are not intended or effective for pain conditions in other parts of the body, such as headaches.


Q: Can children use Flogoral?

A: Official product information confirms that Flogoral is permitted for use in children, but specific guidelines apply based on age and product formulation. For instance, different age restrictions apply to the spray and the mouthwash formulations, with specific dosages defined for different pediatric groups.


Q: What is the typical duration of effect for Flogoral?

A: The pain-relieving effect of Flogoral is generally described as lasting for a short duration. The regulatory-recommended dosing frequency of every 1.5 to 3 hours suggests that the symptomatic relief lasts for several hours per application.


Q: Why is Flogoral sometimes prescribed for dental pain?

A: Flogoral is officially indicated for the relief of pain and inflammation in the mouth and throat, including pain associated with dental procedures and oral surgery. This indication includes conditions such as mouth sores, gum inflammation, and pain resulting from tooth extraction.


Q: What happens if I miss a dose of Flogoral?

A: Product labeling indicates that if a dose is forgotten, the application may be performed as soon as it is recalled. Labeling specifies that an extra application should not be used to compensate for a missed one.


Q: Is it normal to feel a tingling sensation after using Flogoral?

A: Yes, the official product information lists a temporary numb or stinging sensation at the site of application as a common side effect. This sensation is a recognized characteristic of the drug's local anaesthetic properties and generally resolves quickly.


Q: Is Flogoral available over the counter?

A: In many regulatory jurisdictions, the topical formulation of the active ingredient in Flogoral is available for consumers to purchase over the counter at a pharmacy. It may also be supplied via prescription, depending on the specific product and local regulations.


Q: Can older adults use Flogoral?

A: Official guidelines state that Flogoral is approved for use in the adult population, which includes the elderly. There is typically no specific dosage adjustment recommended for older adults.


Q: Is Flogoral safe to use during pregnancy?

A: Regulatory documents advise that use during pregnancy is not recommended due to a lack of sufficient clinical data in pregnant women. Its use is reserved for situations determined by a physician to be clearly necessary.


Q: Is Flogoral habit-forming or addictive?

A: According to the official classification of the drug, the topical formulation of Flogoral is not generally classified as habit-forming.


Q: Is Flogoral suitable for people with asthma?

A: Official safety documents advise that caution should be exercised when Flogoral is used by patients with a history of bronchial asthma. The possibility of precipitating bronchospasm (a tightening of the airways) is a consideration noted in the product information.


Q: How is Flogoral typically eliminated from the body?

A: Once systemically absorbed, Flogoral is predominantly eliminated from the body via the kidney (urine). The drug is excreted partly unchanged and partly as various metabolites, which are the products of the drug being processed by the body.


Q: Does Flogoral interact with birth control pills?

A: Official regulatory documents for the topical formulations currently indicate that no significant drug interactions are known. This finding means there is no official information stating that Flogoral interacts with medications like oral contraceptive pills.


Q: Are there published studies about Flogoral's effectiveness in children?

A: Yes, the product information contains specific dosages and usage instructions for children, establishing that its effectiveness and safety have been studied and verified for the pediatric population. Certain formulations are indicated for use in children as young as 6 years old and even younger with appropriate dosing.


Q: Can Flogoral affect my blood sugar levels?

A: Official regulatory documents for the topical formulations of Flogoral typically do not contain specific information regarding an effect on blood sugar levels.


Q: Does Flogoral affect fertility?

A: Official safety information states that based on animal studies, there is no known evidence that Flogoral affects fertility. However, the exact effect of the topical treatment on human fertility is currently described as not known in regulatory documents.

How should Flogoral be stored and disposed of?

How to Store and Dispose of Flogoral (Benzydamine)

Official regulatory documentation sets specific requirements for the storage and disposal of Flogoral to ensure stability and public safety.

Storage Requirements

Constraint Requirement
Temperature Do not store above 25°C.
Protection Keep in the original outer carton and protect from light and moisture.
Child Safety Must be kept out of the sight and reach of children.
Stability Once opened, the medicine (e.g., mouthwash/spray) must be discarded after 6 months.

Disposal Instructions

Expired or unused Flogoral must be disposed of properly. The medicine must not be thrown away via wastewater or household waste. Disposal should be conducted in accordance with local regulations, typically by returning the product to a pharmacist or using an authorized medicine take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flogoral found in:

A-Z Index: